Terminated PHASE2 INTERVENTIONAL NCT00005608

Fluorouracil-Uracil and Leucovorin in Treating Women With Metastatic Breast Cancer

Orzel (UFT+Leucovorin) as First-Line Therapy for Metastatic Breast Cancer

Sponsor: National Cancer Institute (NCI)

Interventions leucovorin calcium tegafur-uracil

Updated 7 times since 2017 Last updated: May 31, 2012 Started: Feb 29, 2000 Primary completion: Jun 30, 2002 Completion: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Drug was pulled from the market.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

A PHASE2 clinical study on Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States